MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
USA - English
Share this article
MagicMed Industries Inc. (CSE: MGIC reserved) (
MagicMed or the
Company ) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence (
AI ). Together the parties are building PsyAI
TM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine.
The standard pharmaceutical candidate screening process is a consistent bottleneck in bringing standard pharmaceutical candidates to market and acts as a primary determinant of eventual clinical success or failure. This paradigm is particularly challenging in the psychedelics pharmaceutical sector, owing to a limited understanding of the mechanisms underlying observed clinical dat
4 Psychedelics Experts On Adoption In Mainstream Medicine: A Mental Health Revolution
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Accredited Investor email list Some investment opportunities are limited to accredited investors. Whether you are an accredited investor or not depends on where you live and other criteria. For full details go to https://investingnews.com/accredited-investor-definition/ or search for accredited investor in the search bar above.
By completing this form, you are giving consent to receive communication from MagicMed Industries using the contact information you provide. And remember you can unsubscribe at any time.
MagicMed Industries’ Management Team
Dr. Joseph Tucker CEO
Dr. Joseph Tucker is a seasoned executive who has built several publicly traded biotechnology companies. He was a founder and CEO of Stem Cell Therapeutics, which he took public on the TSX. Trillium Therapeutics acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and CEO of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Bioscie
Webcast Information
To attend the live video webcast, please register or email KCSA Strategic Communications at [email protected].
About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, shareholder communications and social media, with expertise in financial and professional services, technology, healthcare, digital media, cannabis and energy. Since 1969, the Firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The Firm s clients are its best references.
For more information, please visit www.kcsa.com.
SOURCE KCSA Strategic Communications
MagicMed Industries Inc. (CSE: MGIC reserved) (
MagicMed or the
Company ) announced today that it has completed the establishment of the psilocybin-derivatives patent portfolio of the Psybrary
TM and the launch of the Candidate Selection program. The Psybrary
TM is a proprietary physical and knowledgebase collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect all of the above.
MagicMed s Chief Scientific Officer, Dr. Peter Facchini, stated Our psilocybin-derivatives portfolio, which also captures dimethyltryptamine (DMT) derivatives, now includes 12 filed patent applications directed to 9 different chemical compound categories covering over 125 million individual molecules. While we certainly don t expect to synthesize all of these molecules during the development of new drug candidates, I am pleased to announce that, as of today s launch of the Candidate Selection program, we have alre
vimarsana © 2020. All Rights Reserved.